Literature DB >> 20881612

Antiangiogenic and antimitotic effects of aspirin in hypoxia–reoxygenation modulation of the LOX-1-NADPH oxidase axis as a potential mechanism.

Magomed Khaidakov1, Jacob Szwedo, Sona Mitra, Srinivas Ayyadevara, Maxim Dobretsov, Jingjun Lu, Jawahar L Mehta.   

Abstract

Hypoxia–reoxygenation (HR) is a primary driver of angiogenesis in both atherogenesis and tumorigenesis. The main target of hypoxia-driven proangiogenic signaling is adherens junctions responsible for contact inhibition of endothelial cells. We analyzed the effects of hypoxia (8–12 hours) followed by a brief period of reoxygenation (2 hours) (HR) on angiogenesis and integrity of adherens junction in cultured human umbilical vein endothelial cells as well as the effects of aspirin on modulation of human umbilical vein endothelial cells' response to HR. Cells exposed to HR displayed considerable enhancement of tube formation (angiogenesis) on matrigel. Immunocytostaining of near-confluent cells revealed that HR caused disruption of adherens junctions and internalization of their components VE-cadherin, p120 catenin, and b-catenin. Additionally, HR resulted in the appearance of binucleated cells, and VE-cadherin in colocalization with b-catenin was found to be positioned between the separating nuclei. Presence of aspirin (acetylsalicylic acid, 1 mM) resulted in preservation of adherens junctions on the cellular membrane and prevented angiogenesis as well as mitosis. HR caused upregulation LOX-1, the p47(phox) subunit of NADPH, while reducing transcription of endothelial nitric oxide synthase. Aspirin had no effect on endothelial nitric oxide synthase and canceled the transcriptional activation of the LOX-1 and p47(phox) subunit of NADPH oxidase. Based on these data, we hypothesize that aspirin preserves the integrity of adherens junctions and thus blunts angiogenic response to HR through downregulation of LOX-1 and the LOX-1-mediated p47(phox) component of NADPH oxidase transcription, thus preventing NADPH oxidase assembly and function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20881612     DOI: 10.1097/FJC.0b013e3181f801e4

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Aspirin Is Associated With Improved Liver Function After Embolization of Hepatocellular Carcinoma.

Authors:  F Edward Boas; Karen T Brown; Etay Ziv; Hooman Yarmohammadi; Constantinos T Sofocleous; Joseph P Erinjeri; James J Harding; Stephen B Solomon
Journal:  AJR Am J Roentgenol       Date:  2019-05-23       Impact factor: 3.959

2.  Adjuvant Medications That Improve Survival after Locoregional Therapy.

Authors:  F Edward Boas; Etay Ziv; Hooman Yarmohammadi; Karen T Brown; Joseph P Erinjeri; Constantinos T Sofocleous; James J Harding; Stephen B Solomon
Journal:  J Vasc Interv Radiol       Date:  2017-05-17       Impact factor: 3.464

Review 3.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

Review 4.  Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?

Authors:  Alessandro Ottaiano; Mariachiara Santorsola; Michele Caraglia; Luisa Circelli; Valerio Gigantino; Gerardo Botti; Guglielmo Nasti
Journal:  Transl Oncol       Date:  2021-05-21       Impact factor: 4.243

5.  Lower dosage of aspirin promotes cell growth and osteogenic differentiation in murine bone marrow stromal cells.

Authors:  Mi Du; Wan Pan; Xiaoqi Duan; Pishan Yang; Shaohua Ge
Journal:  J Dent Sci       Date:  2016-05-13       Impact factor: 2.080

6.  Aggregate Interactome Based on Protein Cross-linking Interfaces Predicts Drug Targets to Limit Aggregation in Neurodegenerative Diseases.

Authors:  Meenakshisundaram Balasubramaniam; Srinivas Ayyadevara; Akshatha Ganne; Samuel Kakraba; Narsimha Reddy Penthala; Xiuxia Du; Peter A Crooks; Sue T Griffin; Robert J Shmookler Reis
Journal:  iScience       Date:  2019-09-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.